---
title: "Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293344159.md"
description: "Our strategic plan is progressing towards developing a new therapeutic drug class utilizing a synthetic recombinant Platelet-Rich Plasma (PRP). This innovative approach targets various chronic diseases and is a pivotal step forward in advancing healthcare. By harnessing the power of synthetic PRP, we aim to enhance treatment options and improve patient outcomes. This milestone signifies a significant advancement in medical research and holds promise for addressing a wide range of health conditions."
datetime: "2026-07-21T12:32:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293344159.md)
  - [en](https://longbridge.com/en/news/293344159.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293344159.md)
generator: "portal-rs"
---

# Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal

Our strategic plan is progressing towards developing a new therapeutic drug class utilizing a synthetic recombinant Platelet-Rich Plasma (PRP). This innovative approach targets various chronic diseases and is a pivotal step forward in advancing healthcare. By harnessing the power of synthetic PRP, we aim to enhance treatment options and improve patient outcomes. This milestone signifies a significant advancement in medical research and holds promise for addressing a wide range of health conditions.

### Related Stocks

- [PPCB.US](https://longbridge.com/en/quote/PPCB.US.md)
- [PPCBD.US](https://longbridge.com/en/quote/PPCBD.US.md)

## Related News & Research

- [Propanc Biopharma Announces Positive Preclinical Data For PRP In Pancreatic Cancer, Stock Soars](https://longbridge.com/en/news/297195775.md)
- [EXCLUSIVE: AI, Genomics Could Fuel Biotech ETF Re-Rating as Health Care Trades at Discount, Says Expert](https://longbridge.com/en/news/297966708.md)
- [FDA approves PharmaEssentia BESREMi for adults with essential thrombocythemia](https://longbridge.com/en/news/297513690.md)
- [Cellectis to present at Baird Global Healthcare Conference](https://longbridge.com/en/news/297695285.md)
- [JPMorgan hires healthcare banker David Blais from Guggenheim, sources say](https://longbridge.com/en/news/298063714.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**